CSL Limited (ASX:CSL) Initiates Manufacturing of Oxford/AstraZeneca’s Vaccine Candidate

  • November 09, 2020 01:03 PM AEDT
  • Team Kalkine
    Team Kalkine
    Team Kalkine
    16964 Posts

    Team Kalkine comprises of experts who understand various markets nuances and are enthusiastic and passionate to provide best possible offerings in the form of insights and stories. The team has rich experience of working across different markets with...

CSL Limited (ASX:CSL) Initiates Manufacturing of Oxford/AstraZeneca’s Vaccine Candidate

Summary

  • CSL Limited starts manufacturing of Oxford/AstraZeneca’s COVID-19 vaccine candidate ‘AZD1222’ in Melbourne.
  • CSL to produce ~30 million doses of the AZD1222, with the first doses slated for release in H1 2021.
  • The Company said that during 2020/2021 it would produce eight large-scale batches of the vaccine.

ASX 200-listed leading global biotechnology player CSL Limited (ASX:CSL) today updated the market that the Company will commence manufacturing the Oxford/AstraZeneca’s COVID-19 vaccine candidate ‘AZD1222’ at its Melbourne facility on 9 November 2020.

The share price of CSL was noted at A$306.960, up by 1.645%, on 9 November 2020 (at AEDT 12:47 PM).  

Let us discuss in detail-

About CSL Limited

Australia-based biotech behemoth CSL Limited has a dynamic portfolio of life-saving drugs. The medicines of CSL are for treatment of immune deficiencies, haemophilia, including vaccines for prevention of influenza.

Through its two businesses - CSL Behring and Seqirus, the Company offers life-saving medicines to over 100 nations.

CSL Commences Manufacturing 30 million doses of AZD1222

On 8 November 2020, CSL Limited stated that it would start manufacturing the University of Oxford/AstraZeneca’s COVID-19 vaccine candidate, AZD1222 at its advanced manufacturing facility in Melbourne from 9 November.

The Company highlighted that it has separate agreements with UK-headquartered AstraZeneca (LON:AZN) as well as the government of Australia to manufacture almost 30 million doses of the vaccine candidate. CSL is planning the release of the first dose in H1 2021, awaiting the clinical trials results and regulatory approval.

Image Source: © Kalkine Group 2020

The biotechnology player added it would not distribute the vaccine until the relevant manufacturing and clinical trial data are reviewed and approved by the TGA.

The TGA has given a provisional determination to the adenovirus vector-based vaccine. Moreover, AstraZeneca will oversee the application for registration for AZD1222 on the ARTG.

It is noteworthy to mention that CSL has scheduled AZD1222 production, along with the manufacturing of UQ-CSL V451 COVID-19 vaccine candidate, at the same time maintaining commitments to produce its vital core biotherapies.

The manufacturing process of COVID-19 vaccine

The process will begin with the thaw of vials comprising vaccine cells. For the integrity preservation, the cells are preserved under liquid nitrogen and need to be thawed for replication in the bioreactors at Broadmeadows facility of CSL.

After developing in the bioreactors, the COVID-19 vaccine is purified, providing a vaccine product or the antigen. The vaccine is then ready for final formulation and filling into the vials.

This vial thaw milestone follows quite a few months of collaboration and planning by technical experts of CSL and AstraZeneca.

Moreover, the Company mentioned that during 2020/2021, it would produce eight large-scale batches of COVID-19 vaccine. After the successful demonstration of the safety and efficacy of AZD1222 in trials, the Company anticipates it will require a two-dose per person regime.

Management Commentary

CSL’s Chief Scientific Officer, Dr Andrew Nash commented-

 

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK